Virtual Library

Start Your Search

Mattia Altini

Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      176P - Real-world treatment patterns for metastatic non-small cell lung cancer at IRST Italy (ID 499)

      12:30 - 13:00  |  Presenting Author(s): Mattia Altini

      • Abstract


      This study sought to describe treatment patterns in terms of real world first-line (1L) and second-line (2L) treatment of metastatic non-small cell lung cancer (NSCLC) prior to the availability of Immunotherapies (IOs) in Italy.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      Metastatic NSCLC pts who initiated anti-cancer systemic treatment at IRST from Jan 2014 to Jun 2017 were included in this retrospective analysis based on electronic health records database, including information on demographics, clinical, tumor, molecular characteristics and treatment(s) administered.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      In total, 440 pts for 1L and 152 for 2L were analyzed. Median age was 69.5 and 65.9 yrs for the 1L and 2L, respectively.

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      In this real world population prior IOs approval in Italy, treatments were largely in line with NSCLC treatment guidelines. As expected, the most frequent type of regimen in 1L setting was platinum doublet and in 2L was single agent chemo.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      Merck & Co., Inc.

      213f68309caaa4ccc14d5f99789640ad Funding

      Merck & Co., Inc.

      682889d0a1d3b50267a69346a750433d Disclosure

      F. Ejzykowicz, S. Chandwani: Employee, shareholder: Merck & Co, Inc. All other authors have declared no conflicts of interest.